Group Introduction
[Its Dual-Listed Companies] Joincare Pharmaceutical Group (Stock Code: 600380 GDR Code：JCARE) Livzon Pharmaceutical Group (Stock Code: 000513 Hong Kong Stock Code: 01513)
Lizhu Monoclonal Antibody Biotechnology Co., Ltd., Zhuhai
Lizhu Monoclonal Antibody Biotechnology Co., Ltd. (Lizhu Monoclonal Antibody), a high-tech enterprise focusing on the development of globally leading innovative macromolecular drugs, was initiated by Lizhu Pharmaceutical Group and Healthyuan Pharmaceutical Group and established in July 2010. Its main business is the research, development, and industrialization of biological drugs. It has a rich R&D product line, including recombinant proteins, antibodies, vaccines, and CAR-T cell therapy products. One product has been launched, one has been submitted for production, and more than 10 products are at other different stages.
The company has an experienced leadership team with an average of more than 15 years of experience in biological drug R&D and industrialization, possessing first-class innovation and industrialization capabilities. It owns a national-level enterprise technology center (antibody drug laboratory); the Lizhu Monoclonal Antibody building covers 17,000 square meters, with 8,000 square meters of R&D laboratories and 200/500/2000L GMP production lines. It possesses a large-scale commercial vaccine workshop (one bulk drug production line and three preparation production lines).
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.